trial · primary record
Toripalimab
Muscle-Invasive Bladder Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 64 |
| Primary completion | 2029-12-31 |
| Primary endpoint | Clinical complete response (cCR) rate |
| Registry ID | NCT05975307 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:12.307Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05975307
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Toripalimab · compound